ESEva Eugenie Rose Segura

Eva Eugenie Rose Segura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eva Eugenie Rose Segura has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Donald Barry Kohn

    University of California, Los Angeles, Los Angeles, California, UNITED STATES

    2 shared publications
  • Andrea Gutierrez Garcia

    Department of Biology at California State University, Northridge, Northridge, CA 91330, USA

    1 shared publication
  • Beatriz Campo Fernandez

    Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA

    1 shared publication
  • Carol Mulumba

    Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA

    1 shared publication
  • Devesh Sharma

    Department of Surgery, Division of Pediatric Surgery at University of California, San Francisco, San Francisco, CA 94143, USA

    1 shared publication
  • Devin Brown

    Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA

    1 shared publication

Latest Publications

  • Open Access

    Lentiviral vectors for hematopoietic stem cell gene therapy restore α-globin expression in α-thalassemia red blood cells

    by Eva E.R. Segura, Kevyn Hart, Beatriz Campo Fernandez, Devin Brown, Kevin Tam, Andrea Gutierrez Garcia, Eva Seigneurbieux, Karen Li, Carol Mulumba, Emma Blakely, et al.


  • Open Access

    Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials

    by Eva Eugenie Rose Segura, Paul George Ayoub, Kevyn Lopez Hart, Donald Barry Kohn

    Investigations to understand the function and control of the globin genes have led to some of the most exciting molecular discoveries and biomedical breakthroughs of the 20th and 21st centuries. Extensive characterization of the globin gene locus, accompanied by pioneering work on the utilization of viruses as human gene delivery tools in human hematopoietic stem and progenitor cells (HPSCs), has led to transformative and successful therapies via autologous hematopoietic stem-cell transplant with gene therapy (HSCT-GT). Due to the advanced understanding of the β-globin gene cluster, the first diseases considered for autologous HSCT-GT were two prevalent β-hemoglobinopathies: sickle cell disease and β-thalassemia, both affecting functional β-globin chains and leading to substantial morbidity. Both conditions are suitable for allogeneic HSCT; however, this therapy comes with serious risks and is most effective using an HLA-matched family donor (which is not available for most patients) to obtain optimal therapeutic and safe benefits. Transplants from unrelated or haplo-identical donors carry higher risks, although they are progressively improving. Conversely, HSCT-GT utilizes the patient’s own HSPCs, broadening access to more patients. Several gene therapy clinical trials have been reported to have achieved significant disease improvement, and more are underway. Based on the safety and the therapeutic success of autologous HSCT-GT, the U.S. Food and Drug Administration (FDA) in 2022 approved an HSCT-GT for β-thalassemia (Zynteglo™). This review illuminates the β-globin gene research journey, adversities faced, and achievements reached; it highlights important molecular and genetic findings of the β-globin locus, describes the predominant globin vectors, and concludes by describing promising results from clinical trials for both sickle cell disease and β-thalassemia.